blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2905620

EP2905620 - METHOD FOR IMAGING CELL USING FLUORESCENCE-LABELED SUGAR DERIVATIVE HAVING COUMARIN DERIVATIVE BOUND THERETO, AND IMAGING AGENT [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.10.2018
Database last updated on 12.07.2024
FormerThe patent has been granted
Status updated on  10.11.2017
FormerGrant of patent is intended
Status updated on  15.06.2017
FormerExamination is in progress
Status updated on  03.03.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Hirosaki University
1, Bunkyo-cho
Hirosaki-shi, Aomori 036-8560 / JP
[2015/33]
Inventor(s)01 / YAMADA, Katsuya
c/o Hirosaki University
1 Bunkyo-cho
Hirosaki-shi Aomori 036-8560 / JP
02 / TESHIMA, Tadashi
c/o Peptide Institute, Inc.
7-2-9 Saito-Asagi
Ibaraki-shi Osaka 567-0085 / JP
03 / YAMAMOTO, Toshihiro
c/o Saito Research Center
Peptide Institue Inc.
7-2-9 Saito-Asagi
Ibaraki-shi Osaka 567-0085 / JP
 [2015/34]
Former [2015/33]01 / YAMADA, Katsuya
c/o Hirosaki University
1 Bunkyo-cho
Hirosaki-shi Aomori 036-8560 / JP
02 / TESHIMA, Tadashi
c/o PEPTIDE INSTITUTE INC.
4-1-2 Ina
Minoh-shi Osaka 562-8686 / JP
03 / YAMAMOTO, Toshihiro
c/o Saito Research Center
Peptide Institue Inc.
7-2-9 Saito-Asagi
Ibaraki-shi Osaka 567-0085 / JP
Representative(s)Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[N/P]
Former [2015/33]Maiwald Patentanwalts GmbH
Elisenhof
Elisenstrasse 3
80335 München / DE
Application number, filing date13843405.501.10.2013
[2015/33]
WO2013JP76629
Priority number, dateJP2012022104903.10.2012         Original published format: JP 2012221049
[2015/33]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014054601
Date:10.04.2014
Language:JA
[2014/15]
Type: A1 Application with search report 
No.:EP2905620
Date:12.08.2015
Language:EN
[2015/33]
Type: B1 Patent specification 
No.:EP2905620
Date:13.12.2017
Language:EN
[2017/50]
Search report(s)International search report - published on:JP10.04.2014
(Supplementary) European search report - dispatched on:EP01.04.2016
ClassificationIPC:G01N33/58, A61K49/00, C07H5/06, C07H15/12, C12Q1/02
[2015/33]
CPC:
A61K49/0039 (EP,CN,US); G01N33/5091 (US); A61K49/0052 (EP,CN,US);
C07H13/10 (EP,CN,US); C07H3/02 (EP,US); G01N33/533 (EP,CN,US);
G01N33/574 (EP,CN,US); G01N33/582 (EP,CN,US); G01N2400/00 (US);
G01N2800/7028 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/33]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN ZUR ZELLBILDGEBUNG MIT EINEM FLUORESZENZMARKIERTEN ZUCKERDERIVAT MIT DARAN GEBUNDENEM CUMARINDERIVAT UND KONTRASTMITTEL[2015/33]
English:METHOD FOR IMAGING CELL USING FLUORESCENCE-LABELED SUGAR DERIVATIVE HAVING COUMARIN DERIVATIVE BOUND THERETO, AND IMAGING AGENT[2015/33]
French:MÉTHODE D'IMAGERIE DE CELLULE UTILISANT UN DÉRIVÉ DE SUCRE MARQUÉ PAR FLUORESCENCE COMPORTANT UN DÉRIVÉ DE COUMARINE LIÉ, ET AGENT D'IMAGERIE[2015/33]
Entry into regional phase16.04.2015Translation filed 
16.04.2015National basic fee paid 
16.04.2015Search fee paid 
16.04.2015Designation fee(s) paid 
16.04.2015Examination fee paid 
Examination procedure16.04.2015Examination requested  [2015/33]
29.09.2016Amendment by applicant (claims and/or description)
03.03.2017Despatch of a communication from the examining division (Time limit: M04)
26.04.2017Reply to a communication from the examining division
16.06.2017Communication of intention to grant the patent
25.09.2017Fee for grant paid
25.09.2017Fee for publishing/printing paid
25.09.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  03.03.2017
Opposition(s)14.09.2018No opposition filed within time limit [2018/47]
Fees paidRenewal fee
29.10.2015Renewal fee patent year 03
27.10.2016Renewal fee patent year 04
30.10.2017Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU01.10.2013
AL13.12.2017
AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
HR13.12.2017
IT13.12.2017
LT13.12.2017
LV13.12.2017
MC13.12.2017
MK13.12.2017
NL13.12.2017
PL13.12.2017
PT13.12.2017
RO13.12.2017
RS13.12.2017
SE13.12.2017
SI13.12.2017
SK13.12.2017
SM13.12.2017
TR13.12.2017
BG13.03.2018
NO13.03.2018
GR14.03.2018
IS13.04.2018
[2020/34]
Former [2020/31]HU01.10.2013
AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
HR13.12.2017
IT13.12.2017
LT13.12.2017
LV13.12.2017
MC13.12.2017
MK13.12.2017
NL13.12.2017
PL13.12.2017
PT13.12.2017
RO13.12.2017
RS13.12.2017
SE13.12.2017
SI13.12.2017
SK13.12.2017
SM13.12.2017
TR13.12.2017
BG13.03.2018
NO13.03.2018
GR14.03.2018
IS13.04.2018
Former [2020/30]AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
HR13.12.2017
IT13.12.2017
LT13.12.2017
LV13.12.2017
MC13.12.2017
NL13.12.2017
PL13.12.2017
PT13.12.2017
RO13.12.2017
RS13.12.2017
SE13.12.2017
SI13.12.2017
SK13.12.2017
SM13.12.2017
TR13.12.2017
BG13.03.2018
NO13.03.2018
GR14.03.2018
IS13.04.2018
Former [2020/28]AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
HR13.12.2017
IT13.12.2017
LV13.12.2017
MC13.12.2017
NL13.12.2017
PL13.12.2017
PT13.12.2017
RO13.12.2017
RS13.12.2017
SE13.12.2017
SI13.12.2017
SK13.12.2017
SM13.12.2017
TR13.12.2017
BG13.03.2018
NO13.03.2018
GR14.03.2018
IS13.04.2018
Former [2020/16]AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
HR13.12.2017
IT13.12.2017
LV13.12.2017
MC13.12.2017
NL13.12.2017
PL13.12.2017
RO13.12.2017
RS13.12.2017
SE13.12.2017
SI13.12.2017
SK13.12.2017
SM13.12.2017
TR13.12.2017
BG13.03.2018
NO13.03.2018
GR14.03.2018
IS13.04.2018
Former [2019/28]AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
HR13.12.2017
IT13.12.2017
LV13.12.2017
MC13.12.2017
NL13.12.2017
PL13.12.2017
RO13.12.2017
RS13.12.2017
SE13.12.2017
SI13.12.2017
SK13.12.2017
SM13.12.2017
BG13.03.2018
NO13.03.2018
GR14.03.2018
IS13.04.2018
Former [2019/13]AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
HR13.12.2017
IT13.12.2017
LV13.12.2017
NL13.12.2017
PL13.12.2017
RO13.12.2017
RS13.12.2017
SE13.12.2017
SI13.12.2017
SK13.12.2017
SM13.12.2017
BG13.03.2018
NO13.03.2018
GR14.03.2018
IS13.04.2018
Former [2018/51]AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
HR13.12.2017
IT13.12.2017
LV13.12.2017
NL13.12.2017
PL13.12.2017
RO13.12.2017
RS13.12.2017
SE13.12.2017
SK13.12.2017
SM13.12.2017
BG13.03.2018
NO13.03.2018
GR14.03.2018
IS13.04.2018
Former [2018/40]AT13.12.2017
CY13.12.2017
CZ13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
HR13.12.2017
IT13.12.2017
LV13.12.2017
NL13.12.2017
PL13.12.2017
RO13.12.2017
RS13.12.2017
SE13.12.2017
SK13.12.2017
SM13.12.2017
BG13.03.2018
NO13.03.2018
GR14.03.2018
IS13.04.2018
Former [2018/39]AT13.12.2017
CY13.12.2017
CZ13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
HR13.12.2017
IT13.12.2017
LV13.12.2017
NL13.12.2017
PL13.12.2017
RS13.12.2017
SE13.12.2017
SK13.12.2017
SM13.12.2017
BG13.03.2018
NO13.03.2018
GR14.03.2018
IS13.04.2018
Former [2018/38]AT13.12.2017
CY13.12.2017
CZ13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
HR13.12.2017
LV13.12.2017
NL13.12.2017
PL13.12.2017
RS13.12.2017
SE13.12.2017
SK13.12.2017
SM13.12.2017
BG13.03.2018
NO13.03.2018
GR14.03.2018
IS13.04.2018
Former [2018/37]CY13.12.2017
CZ13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
HR13.12.2017
LV13.12.2017
NL13.12.2017
PL13.12.2017
RS13.12.2017
SE13.12.2017
SK13.12.2017
SM13.12.2017
BG13.03.2018
NO13.03.2018
GR14.03.2018
Former [2018/34]FI13.12.2017
HR13.12.2017
LV13.12.2017
NL13.12.2017
RS13.12.2017
SE13.12.2017
BG13.03.2018
NO13.03.2018
GR14.03.2018
Former [2018/24]FI13.12.2017
HR13.12.2017
LV13.12.2017
RS13.12.2017
SE13.12.2017
BG13.03.2018
NO13.03.2018
GR14.03.2018
Former [2018/22]FI13.12.2017
NO13.03.2018
Documents cited:Search[X]US5830912  (GEE KYLE R [US], et al) [X] 1,2,6 * Abstract; examples 20, 21; compounds 21, 22; claim 21. *;
 [A]WO03059149  (THRESHOLD PHARMACEUTICALS INC [US], et al) [A] 1-15 * Abstract; p. 1', l. 26; claim 1. *;
 [Y]WO2011098610  (UNIV FIRENZE [IT], et al) [Y] 1-15 * Abstract; claim 29. *;
 [YD]WO2012070024  (METASIGNAL THERAPEUTICS INC [CA], et al) [YD] 1-15* Abstract; p. 6-7 *;
 [A]  - NITIN NITIN ET AL, "Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy-glucose", INTERNATIONAL JOURNAL OF CANCER, US, (20090601), vol. 124, no. 11, doi:10.1002/ijc.24222, ISSN 0020-7136, pages 2634 - 2642, XP055259087 [A] 1-15 * Abstract. *

DOI:   http://dx.doi.org/10.1002/ijc.24222
 [A]  - JELENA LEVI ET AL, "Fluorescent Fructose Derivatives for Imaging Breast Cancer Cells", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 18, no. 3, doi:10.1021/BC060184S, ISSN 1043-1802, (20070501), pages 628 - 634, (20070420), XP008142401 [A] 1-15 * Abstract; compounds 4, 5. *

DOI:   http://dx.doi.org/10.1021/bc060184s
International search[A]JPH0720131  (NAKANO VINEGAR CO LTD);
 [A]JPH10267931  (TAKARA SHUZO CO, et al);
 [A]JP2001524969  (CARNEGIE MELLON UNIVERSITY);
 [A]WO2005108979  (AJINOMOTO KK [JP], et al);
 [A]JP2009190993  (KITASATO INST, et al);
 [A]WO2010027108  (TOKYO INST TECH [JP], et al);
 [A]JP2011153096  (KANEKA CORP);
 [A]WO2012038614  (J SOUFFLET ETS [FR], et al);
 [A]WO2012070024  (METASIGNAL THERAPEUTICS INC [CA], et al);
 [A]  - CLAUDIU T SUPURAN, "Inhibition of carbonic anhydrase IX as a novel anticancer mechanism", WORLD J CLIN ONCOL, (201207), vol. 3, no. 7, pages 98 - 103, XP002721203

DOI:   http://dx.doi.org/10.5306/WJCO.V3.I7.98
by applicantUS6989140
 WO2010016587
 WO2012070024
    - FUKUDA, H. ET AL., EUR. J. NUCL. MED., (1986), vol. 11, pages 444 - 448
    - IWASHITA, K. ET AL., INT. J. RAD. APPL. INSTRUM. B., (1989), vol. 16, pages 247 - 254
    - WUEST, M. ET AL., NUC.. MED. BIOL., (2011), vol. 38, pages 461 - 475
    - IDO, T. ET AL., J. LABELLED COMOPOUNDS AND RADIOPHARMACEUTICALS, (1978), vol. 14, pages 175 - 183
    - FUKUDA, H. ET AL., EUR. J. NUCL. MED., (1982), vol. 7, pages 294 - 297
    - YAMADA K. ET AL., J. BIOL. CHEM., (2000), vol. 275, pages 22278 - 22283
    - YAMADA K. ET AL., NAT. PROTOC., (2007), vol. 2, pages 753 - 762
    - LEVI, J. ET AL., BIOCONJUG. CHEM., (2007), vol. 18, pages 628 - 634
    - O'NEIL ET AL., MOL. IMAGING BIOL., (2005), vol. 7, pages 388 - 392
    - SHETH ET AL., J. BIOMED. OPT., (2009), vol. 14, pages 064014 - 1,8
    - NITIN ET AL., INT. J. CANCER, (2009), vol. 124, pages 2634 - 2642
    - CHENG Z. ET AL., BIOCONJUGATE CHEM., (2006), vol. 17, pages 662 - 669
    - TIAN YS. ET AL., ANGEW CHEM INT ED., (2009), vol. 48, pages 802 - 8031
    - KOVAR JL ET AL., ANAL. BIOCHEM., (2009), vol. 384, pages 254 - 262
    - SUPURAN, C.T., NAT. REV. DRUG DISCOV., (2008), vol. 7, pages 168 - 181
    - MARESCA, A.; SUPURAN, C.T., BIOORG. MED. CHEM. LETT., (2010), vol. 20, pages 4511 - 4514
    - SUPURAN, C.T., WORLD J. CLIN. ONCOL., (2012), vol. 3, pages 98 - 103
    - KOVAR JL ET AL., ANAL. BIOCHEM., (2007), vol. 367, pages 1 - 12
    - BRISTOW, R.G.; HILL, R.P., NAT. REV. CANCER, (2008), vol. 8, pages 180 - 192
    - DENKO N.C., NAT. REV. CANCER, (2008), vol. 8, pages 705 - 713
    - SUPURAN, C.T., NAT. REV. DRUG DISCOV., (2011), vol. 10, pages 767 - 777
 WO2012JP58439
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.